STOCK TITAN

Rhythm (NASDAQ: RYTM) CTO sells 5,079 shares in 10b5-1 plan

(Very High)
(Negative)
Form Type
4

Rhea-AI Filing Summary

RHYTHM PHARMACEUTICALS, INC. executive Joseph Shulman, Chief Technical Officer, exercised 2,024 stock options at an exercise price of $6.80 per share into common stock on 2026-08-13 and sold 5,079 common shares at $119.75 per share. The options, granted on 2022-02-09 and vesting in 16 installments, now show 5,945 options reported as remaining. These transactions were effected under a Rule 10b5-1 trading plan adopted on 2025-12-15.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Shulman Joseph
Role Chief Technical Officer
Sold 5,079 shs ($608K)
Approx. gross sale proceeds $608K
Approx. exercise cost $14K
Type Security Shares Price Value
Exercise Stock Options (Right to Buy) F1, F2 2,024 $0.00 $0.00
Exercise Common Stock F1 2,024 $6.80 $14K
Sale Common Stock F1 5,079 $119.75 $608K
Holdings After Transaction: Stock Options (Right to Buy) — 5,945 shares (Direct); Common Stock — 15,915 shares (Direct)
Footnotes (2)
  1. F1. The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025.
  2. F2. The stock options were granted on February 9, 2022. The options vested and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
Options Exercised 2,024 shares Stock options exercised into common stock on 2026-08-13
Exercise Price $6.80 per share Exercise price of stock options exercised on 2026-08-13
Shares Sold 5,079 shares Common stock sale on 2026-08-13
Sale Price $119.75 per share Per-share price for common stock sold on 2026-08-13
Options Remaining 5,945 options Stock options reported as held following the option exercise
Option Expiration 2032-02-08 Expiration date of the stock options exercised
10b5-1 Plan Adoption Date 2025-12-15 Date Shulman adopted Rule 10b5-1 trading plan covering these trades
Rule 10b5-1 trading plan financial
"were effected pursuant to a Rule 10b5-1 trading plan adopted"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
stock options financial
"The stock options were granted on February 9, 2022."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
exercise price financial
"conversion_or_exercise_price: "6.8000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

What did RYTM’s Chief Technical Officer report in this Form 4?

RHYTHM PHARMACEUTICALS (RYTM) CTO Joseph Shulman reported exercising 2,024 stock options at $6.80 per share and selling 5,079 common shares at $119.75 per share on 2026-08-13, as part of an options exercise and share sale sequence.

How many RYTM stock options did Joseph Shulman exercise and at what price?

Joseph Shulman exercised 2,024 stock options in RHYTHM PHARMACEUTICALS (RYTM) at an exercise price of $6.80 per share. These options converted into an equal number of common shares as part of a derivative exercise transaction reported on 2026-08-13.

How many RYTM shares did Joseph Shulman sell and at what price?

Shulman sold 5,079 shares of RHYTHM PHARMACEUTICALS (RYTM) common stock at a price of $119.75 per share. The sale occurred on 2026-08-13 and is reported as a non-derivative transaction coded as a sale in the Form 4 filing.

Were Joseph Shulman’s RYTM transactions under a Rule 10b5-1 trading plan?

Yes. The Form 4 states the exercise and sale were effected pursuant to a Rule 10b5-1 trading plan for RHYTHM PHARMACEUTICALS (RYTM), which Shulman adopted on 2025-12-15, indicating the trades followed a pre-established trading arrangement.

What RYTM options holdings remain for Joseph Shulman after the reported exercise?

After exercising 2,024 stock options, Shulman is reported as holding 5,945 stock options in RHYTHM PHARMACEUTICALS (RYTM). These options relate to a grant dated 2022-02-09, with vesting in 16 substantially equal installments tied to successive service.

When were Joseph Shulman’s RYTM stock options granted and when do they expire?

The RHYTHM PHARMACEUTICALS (RYTM) stock options were granted to Shulman on 2022-02-09 and expire on 2032-02-08. They vest and become exercisable in 16 substantially equal installments based on continued three-month service intervals following the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Shulman Joseph

(Last)(First)(Middle)
C/O RHYTHM PHARMACEUTICALS, INC.
222 BERKELEY STREET, 12TH FLOOR

(Street)
BOSTON MASSACHUSETTS 02116

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Technical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/13/2026M(1)2,024A$6.820,994D
Common Stock08/13/2026S(1)5,079D$119.7515,915D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options (Right to Buy)$6.808/13/2026M(1)2,024 (2)02/08/2032Common Stock2,024$05,945D
Explanation of Responses:
1. The Exercise and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025.
2. The stock options were granted on February 9, 2022. The options vested and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
/s/ Stephen Vander Stoep, attorney-in-fact for Joseph Shulman08/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)